allo-20240605

0001737287-24-000050.txt : 20240610 0001737287-24-000050.hdr.sgml : 20240610 20240610163058 ACCESSION NUMBER: 0001737287-24-000050 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240605 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240610 DATE AS OF CHANGE: 20240610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allogene Therapeutics, Inc. CENTRAL INDEX KEY: 0001737287 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 823562771 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38693 FILM NUMBER: 241033196 BUSINESS ADDRESS: STREET 1: 210 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 457-2700 MAIL ADDRESS: STREET 1: 210 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 allo-20240605.htm 8-K allo-20240605

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________

FORM 8-K

____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 5, 2024

_______________________

Allogene Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

____________________________


Delaware	001-38693	82-3562771
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

210 East Grand Avenue, South San Francisco, California 94080

(Address of principal executive offices including zip code)

Registrant’s telephone number, including area code: (650) 457-2700

(Former name or former address, if changed since last report.)

________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


			☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
			☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
			☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
			☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.001 par value per share

ALLO

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 5, 2024, the Board of Directors of Allogene Therapeutics, Inc. (the “Company”) appointed Annie Yoshiyama, the Company’s current Senior Vice President and Corporate Controller, as the Company’s principal accounting officer, effective immediately, replacing Geoffrey Parker in such capacity. Mr. Parker continues to serve as the Company’s Chief Financial Officer and principal financial officer.

Prior to joining the Company in April 2024, Ms. Yoshiyama, age 41, served as Vice President, Finance & Controller at AN2 Therapeutics, Inc. from September 2023 to March 2024; Senior Vice President ‒ Finance and Chief Accounting Officer, Vice President ‒ Finance and Chief Accounting Officer, Executive Director ‒ Finance, Senior Director ‒ Finance, Director ‒ SEC Reporting and Technical Accounting, and Associate Director ‒ SEC Reporting and Technical Accounting at Tricida, Inc. from June 2018 to March 2023; Senior Financial Reporting and Technical Accounting Manager at Dolby Laboratories from September 2008 to June 2018; and started her career in audit at PricewaterhouseCoopers LLP from September 2005 to August 2007. Ms. Yoshiyama earned her Bachelor of Science and Master of Accounting degrees from the University of Southern California and is a licensed certified public accountant.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 5, 2024, Allogene Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 17, 2024, the record date for the Annual Meeting, 170,723,100 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

Proposal 1. Election of Directors

The Company’s stockholders elected the four persons listed below as Class III Directors, each to serve until the Company’s 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows:


	Votes For	Votes Withheld	Broker Non-Votes
John DeYoung	121,177,479	17,019,993	15,800,932
Franz Humer, Ph.D.	119,919,567	18,277,905	15,800,932
Joshua Kazam	127,917,055	10,280,417	15,800,932
Stephen Mayo, Ph.D.	130,166,905	8,030,567	15,800,932

Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement for the Annual Meeting. The final voting results are as follows:


Votes For	Votes Against	Abstentions	Broker Non-Votes
119,741,038	16,298,878	2,157,556	15,800,932

Proposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The final voting results are as follows:


Votes For	Votes Against	Abstentions	Broker Non-Votes
152,503,468	1,359,400	135,536	0

Item 9.01 Financial Statements and Exhibits.


(d)
Exhibit Number						Description
104						The cover page of this report has been formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



			ALLOGENE THERAPEUTICS, INC.

			By:			/s/ David Chang, M.D., Ph.D.
						David Chang, M.D., Ph.D.
						President, Chief Executive Officer

Dated: June 10, 2024

EX-101.SCH 2 allo-20240605.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 allo-20240605_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cover [Abstract] Cover [Abstract] Written Communications Written Communications Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security City Area Code City Area Code Document Period End Date Document Period End Date Entity Tax Identification Number Entity Tax Identification Number Amendment Flag Amendment Flag Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Pre-commencement Tender Offer Pre-commencement Tender Offer Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 allo-20240605_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information Document	Jun. 05, 2024
Cover [Abstract]
Document Type	8-K
Document Period End Date	Jun. 05, 2024
Entity Registrant Name	Allogene Therapeutics, Inc.
Entity Central Index Key	0001737287
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity File Number	001-38693
Entity Tax Identification Number	82-3562771
Entity Address, Address Line One	210 East Grand Avenue
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	650
Local Phone Number	457-2700
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	ALLO
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Document Sheet http://allogene.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports allo-20240605.htm allo-20240605.xsd allo-20240605_lab.xml allo-20240605_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "allo-20240605.htm": { "nsprefix": "allo", "nsuri": "http://allogene.com/20240605", "dts": { "inline": { "local": [ "allo-20240605.htm" ] }, "schema": { "local": [ "allo-20240605.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "labelLink": { "local": [ "allo-20240605_lab.xml" ] }, "presentationLink": { "local": [ "allo-20240605_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://allogene.com/role/DocumentandEntityInformationDocument", "longName": "0000001 - Document - Document and Entity Information Document", "shortName": "Document and Entity Information Document", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "allo-20240605.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "allo-20240605.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://allogene.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001737287-24-000050-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001737287-24-000050-xbrl.zip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end XML 16 allo-20240605_htm.xml IDEA: XBRL DOCUMENT 0001737287 2024-06-05 2024-06-05 0001737287 false 8-K 2024-06-05 Allogene Therapeutics, Inc. DE 001-38693 82-3562771 210 East Grand Avenue South San Francisco CA 94080 650 457-2700 false false false false Common Stock, $0.001 par value per share ALLO NASDAQ false